- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04133649
Evaluation of Safety and Tolerability of Libella Gene Therapy for the Treatment of Aging: AAV- hTERT
Evaluation of Safety and Tolerability of Libella Gene Therapy (LGT) for the Treatment of Aging: AAV- hTERT
Using gene therapy to express active telomerase (hTERT) in humans has the potential to treat many of the age related diseases, including Aging itself.
This study will entail treating subjects with hTERT delivered via transduction using AAV. The goal is to extend the telomeres to prevent, delay, or even reverse Aging.
Study Overview
Detailed Description
Subjects willing to participate who meet with the inclusion - exclusion criteria, will be treated with a single dose of LGT delivered intravascularly (IV).
Baseline will be performed within 8 weeks of beginning the treatment regimen. The treatment regimen will begin with IV delivery of AAV-hTERT, defined as "Day 0." Safety and efficacy analyses will be conducted at Weeks 1, 4, 13, 26, 39, and 52 post-treatment.
Study objectives
Primary: Safety and Tolerability
1. Investigate the safety and tolerability of AAV-hTERT by intravenous (IV) administration.
Secondary: Provisional Efficacy
- To determine changes from baseline in hTERT expression, telomerase activity, and telomere length in cells after treatment with AAV-hTERT.
- To determine changes from baseline in health and aging-related biomarkers after treatment with AAV-hTERT.
- To determine changes from baseline in the immune system after treatment with AAV-hTERT.
- To determine changes from baseline in physical function measures after treatment with AAV-hTERT
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Cundinamarca
-
Zipaquirá, Cundinamarca, Colombia, 250251
- Recruiting
- IPS Arcasalud SAS
-
Contact:
- Wiston Pernet, MD
- Phone Number: 57 3006840951
- Email: wirapeca@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Subjects must meet the following inclusion criteria at the screening visit.
- Age of 45 years or older.
- Subjects, or their authorized representatives, must be adequately informed and understand the nature and risks of the study and must be able to provide a signature and date in the Informed Consent Form (ICF).
- Women must undergo a negative serum pregnancy test at the screening assessment.
- Subjects, or their representatives, must be able to communicate effectively with the study staff.
- Subjects, or their authorized representatives, must certify that they are able and willing to follow all protocol requirements and study restrictions.
Exclusion Criteria:
Subjects are not eligible for the study if they meet any of the following criteria at the screening visit, unless otherwise specified.
- Subjects who have a history of allergy, hypersensitivity, or intolerance to any medications, components, or excipients of the investigational product, which cannot be resolved by the staff conducting the study.
- Female subjects who are pregnant, expected to become pregnant, or lactating/nursing.
- Subjects who are sexually active and who are unwilling or unable to use a method of effective contraception (e.g., hormonal and/or barrier) during their participation in the study.
- Subjects who are intolerant of, or do not wish to receive, IV or IT injections.
- Subjects who are currently alcoholics and/or use psychoactive substances.
- Subjects who cannot tolerate venipuncture and/or venous access.
- Subjects who have donated or had a significant loss of whole blood (480 ml or more) within 30 days, or donated plasma or platelets within 14 days prior to screening.
- Subjects who have received blood or blood products within 30 days prior to screening.
- Subjects who have been treated with another research product 30 days prior to the screening assessment, or plan to participate in another clinical trial, while in this study if in the opinion of the principal investigator, may place the subject at risk due to participation in the study, or may influence the results of the study or the subject's ability to complete the study. If more than 30 days have passed since participation in another clinical trial, the study staff must ensure that the subject has recovered from any adverse event (AE) associated with the research product used.
- Subjects who have a history or evidence of active infection or febrile illness within 7 days prior to the screening assessment.
Subjects who have a history of any other clinically significant disease or disorder that, in the opinion of the principal investigator, may place the subject at risk due to participation in the study, or may influence the results of the study or the subject's ability to complete the study.
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: subjects treated with LGT
Subjects will be treated with a single IV dose of LGT (AAV-hTERT)
|
subjects will receive a single LGT (AAV-hTERT) treatment via IV administration
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events
Time Frame: 12 months
|
Incidence of serious adverse events and adverse events throughout the study
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
hTERT expression and telomerase activity
Time Frame: 12 months
|
Change from baseline in telomere length
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Winston Pernet, MD, IPS Arcaslud SAS
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- LibellaCO-03
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aging
-
Tuba MadenCompletedAging | Aging Problems | Aging Disorder
-
Radboud University Medical CenterNot yet recruitingAging | Aging Well | Immuno Aging
-
University of Santiago de CompostelaEuropean Regional Development Fund; Center for Industrial Technological Development...Completed
-
TruDiagnosticBlushield USANot yet recruitingAging | Aging Well
-
San Diego State UniversityCompleted
-
Lithuanian Sports UniversityCompletedAging | Healthy AgingLithuania
-
University of West AtticaNot yet recruiting
-
University of Santiago de CompostelaAgencia Estatal de Investigación, SpainRecruiting
-
Beijing HospitalBGI-ShenzhenCompletedAging | Healthy Aging
-
Amazentis SAproDERM GmbHCompleted
Clinical Trials on AAV-hTERT
-
Libella Gene TherapeuticsUnknownEvaluation of Safety and Tolerability of Libella Gene Therapy for Critical Limb Ischemia: AAV- hTERTCritical Limb IschemiaColombia
-
Libella Gene TherapeuticsUnknownAlzheimer DiseaseColombia
-
MeiraGTx UK II LtdSyne Qua Non Limited; EMAS PharmaCompletedAchromatopsiaUnited Kingdom, United States
-
Terence FlotteMassachusetts General Hospital; University of Massachusetts, WorcesterActive, not recruitingTay-Sachs Disease | Sandhoff DiseaseUnited States
-
MeiraGTx UK II LtdCompletedLeber Congenital AmaurosisUnited Kingdom, United States
-
MeiraGTx UK II LtdSyne Qua Non Limited; EMAS PharmaCompleted
-
Abramson Cancer Center of the University of PennsylvaniaCompleted
-
MeiraGTx UK II LtdSyne Qua Non LimitedCompletedEye Diseases | Retinal Diseases | Eye Diseases, Hereditary | Leber Congenital Amaurosis (LCA)United States, United Kingdom
-
University of FloridaWithdrawnMetastatic Prostate Cancer
-
VegaVect, Inc.National Eye Institute (NEI)Active, not recruiting